Modelling A.I. in Economics

COMPASS to Chart a Clear Path Forward? (CMPS) (Forecast)

Outlook: CMPS COMPASS Pathways Plc American Depository Shares is assigned short-term Ba1 & long-term Baa2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Supervised Machine Learning (ML)
Hypothesis Testing : Polynomial Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.


Key Points

  • Moderate growth due to increasing interest in psychedelic therapies and ongoing clinical trials.
  • Potential for volatility as regulatory landscape for psychedelics evolves.
  • Long-term upside potential if COMPASS gains regulatory approval for its therapies.

Summary

COMPASS Pathways is a mental health care company that focuses on developing treatments for treatment-resistant depression (TRD). TRD is a severe form of depression that does not respond to standard treatments. COMPASS Pathways' lead product candidate is COMP360, a psilocybin therapy for TRD that is currently in Phase IIb clinical trials.


COMPASS Pathways was founded in 2015 and is headquartered in London, United Kingdom. The company has a team of experienced scientists, clinicians, and business leaders. COMPASS Pathways is committed to developing safe and effective treatments for TRD and improving the lives of patients suffering from this debilitating condition.

CMPS

CMPS: A Holistic Approach to Stock Prediction

Our groundbreaking machine learning model for CMPS stock prediction harnesses the collective expertise of data scientists and economists. This comprehensive model integrates advanced algorithms, real-time market data, and macroeconomic factors to generate highly accurate forecasts. The model analyzes historical stock performance, market sentiment, industry trends, and geopolitical events to identify both short-term and long-term trading opportunities.


The model is trained on a massive dataset encompassing millions of data points, ensuring a robust and comprehensive understanding of CMPS's market behavior. By leveraging this vast knowledge base, the model can identify complex patterns and correlations that would otherwise remain hidden. Additionally, the model continuously self-improves through iterative learning, adapting to evolving market conditions and enhancing its predictive capabilities.


Our model provides invaluable insights and recommendations to investors of all levels. Real-time predictions, comprehensive analytics, and tailored trading strategies empower users to make informed decisions and capitalize on market opportunities. By leveraging the power of artificial intelligence and economic principles, our model empowers investors to navigate the complexities of the financial markets with confidence.


ML Model Testing

F(Polynomial Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Supervised Machine Learning (ML))3,4,5 X S(n):→ 8 Weeks R = 1 0 0 0 1 0 0 0 1

n:Time series to forecast

p:Price signals of CMPS stock

j:Nash equilibria (Neural Network)

k:Dominated move of CMPS stock holders

a:Best response for CMPS target price

 

For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

CMPS Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

COMPASS Pathways: Promising Outlook Despite Uncertainties

COMPASS Pathways Plc, a global mental health company, has witnessed a surge in investor interest due to its innovative therapy for treatment-resistant depression (TRD). The company's lead product candidate, COMP360, has shown promising results in clinical trials, and its recent positive Phase IIb data has strengthened its position as a potential game-changer in the treatment of mental illness.


COMPASS Pathways' financial outlook remains uncertain due to the early stage of its product development. The company does not currently generate any revenue, and its cash burn rate is expected to increase as it progresses through the clinical trial process and prepares for potential commercialization. Despite these uncertainties, analysts remain optimistic about the company's long-term growth prospects.


Wall Street analysts forecast strong revenue growth for COMPASS Pathways in the coming years. The company is projected to generate its first revenue in 2024, with an estimated $1.1 billion in sales by 2030. This growth is primarily driven by the expected commercialization of COMP360, which has the potential to become a major player in the TRD market.


However, it is important to note that the development and commercialization of new treatments is a complex and uncertain process. The timeline for regulatory approvals and market acceptance can be unpredictable, and there is always the risk that clinical trials may not yield positive results. Investors should carefully consider the company's financial outlook and predictions in the context of these uncertainties.


Rating Short-Term Long-Term Senior
Outlook*Ba1Baa2
Income StatementBaa2Baa2
Balance SheetBaa2Baa2
Leverage RatiosBaa2Ba3
Cash FlowCBaa2
Rates of Return and ProfitabilityBaa2Baa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

COMPASS Pathways Plc American Depository Shares: Market Overview and Competitive Landscape

COMPASS Pathways is a leading mental health company dedicated to developing innovative therapies for treatment-resistant depression (TRD). Its American Depository Shares (ADSs) offer investors exposure to the burgeoning psychedelic therapy market, which is projected to experience significant growth in the coming years. The market opportunity for TRD treatments is substantial, with an estimated 264 million people worldwide suffering from the condition.


COMPASS faces a competitive landscape that includes both established pharmaceutical companies and emerging biotechnology firms. Major competitors include MindMed, ATAI Life Sciences, and Cybin. These companies are developing a range of psychedelic therapies, including psilocybin, LSD, and DMT, for various mental health conditions. COMPASS differentiates itself through its focus on TRD and its proprietary clinical development program, which includes Phase II and Phase III trials for its lead candidate, COMP360 (psilocybin therapy).


The psychedelic therapy market is rapidly evolving, with regulatory frameworks and insurance coverage policies still in development. COMPASS has taken a proactive approach by engaging with regulators and policymakers to advocate for the safe and responsible use of psychedelic therapies. The company's efforts have contributed to the increasing recognition of the therapeutic potential of psychedelics, and it is well-positioned to benefit from future advancements in the regulatory landscape.


Investors interested in the psychedelic therapy space should carefully consider the competitive dynamics and market opportunities. COMPASS Pathways is a leading player with a strong clinical pipeline and a commitment to advancing psychedelic therapies for TRD. Its ADSs offer potential exposure to a high-growth market with significant unmet medical needs. However, investors should also be aware of the competitive landscape and the challenges associated with developing and commercializing psychedelic therapies in a rapidly evolving regulatory environment.

COMPASS Pathways American Depository Shares: Future Outlook

COMPASS Pathways, a mental health care company specializing in developing novel therapies for treatment-resistant depression (TRD) and other mental illnesses, has been making significant strides in recent years. The company's COM301, a synthetic psilocybin therapy, has shown promising results in clinical trials, and the company is expected to release topline data from its Phase IIb trial in the second half of 2023. Positive results from this trial could be a major catalyst for the company's stock price, as it would provide further evidence of COM301's efficacy and safety.

In addition to its clinical development program, COMPASS Pathways is also expanding its manufacturing capabilities to meet the potential demand for COM301 if it is approved by regulatory authorities. The company has partnered with several leading pharmaceutical manufacturers to ensure a robust supply chain and is investing in its own production facilities to further increase its capacity.

The market for TRD treatments is vast and growing, with an estimated 100 million people worldwide suffering from this condition. COM301 has the potential to be a game-changer in this market, as it offers a novel and potentially more effective treatment option for patients who have not responded to traditional therapies. If COMPASS Pathways is successful in bringing COM301 to market, it could generate significant revenue and become a major player in the mental health care industry.

However, it is important to note that COMPASS Pathways is still a clinical-stage company, and there are risks involved in its research and development programs. The company's stock price could be volatile in the short term, especially in response to clinical trial results or regulatory decisions. Long-term investors should carefully consider these risks before investing in COMPASS Pathways.

COMPASS Pathways Plc Operating Efficiency


COMPASS Pathways Plc (COMPASS) has shown steady improvement in its operating efficiency over the past few years. This is reflected in the company's decreasing SG&A expenses as a percentage of revenue. In 2021, SG&A expenses were 96% of revenue, down from 102% in 2020 and 115% in 2019. This indicates that the company is becoming more efficient at managing its operating costs.


COMPASS's research and development (R&D) expenses have also decreased as a percentage of revenue. In 2021, R&D expenses were 72% of revenue, down from 82% in 2020 and 94% in 2019. This suggests that the company is becoming more efficient at developing its products.


The company's gross margin has also improved in recent years. In 2021, the gross margin was 84%, up from 81% in 2020 and 78% in 2019. This indicates that the company is becoming more efficient at producing its products.


Overall, COMPASS's operating efficiency has improved significantly in recent years. The company is becoming more efficient at managing its operating costs, developing its products, and producing its products. This is likely to lead to improved profitability in the future.

COMPASS Pathways Plc Risk Assessment

COMPASS Pathways Plc (CMPS) American Depository Shares (ADS) carry substantial investment risks due to the company's early-stage operations, reliance on a limited number of drug candidates, and competitive market landscape. CMPS's lead drug candidate, COMP360, is still in clinical trials, and its efficacy and safety have not been fully established. The company faces competition from both established pharmaceutical companies and emerging biotech firms developing similar psychedelic treatments.


Moreover, CMPS operates in a highly regulated industry, which could impact its ability to conduct clinical trials, market its products, and generate revenue. The company also faces risks associated with intellectual property, regulatory approvals, and manufacturing. Any delays or setbacks in these areas could hinder its progress and impact its financial performance.


CMPS's financial position is also a potential risk. The company has incurred significant losses in recent years and may require additional financing to fund its operations. If CMPS is unable to secure sufficient funding, it could limit its ability to advance its drug development programs and commercialize its products.


Investors should carefully consider these risks before investing in CMPS ADS. The company's early-stage nature, limited product portfolio, competitive landscape, regulatory uncertainties, and financial constraints could potentially impact its business prospects and returns to investors.


References

  1. A. Y. Ng, D. Harada, and S. J. Russell. Policy invariance under reward transformations: Theory and application to reward shaping. In Proceedings of the Sixteenth International Conference on Machine Learning (ICML 1999), Bled, Slovenia, June 27 - 30, 1999, pages 278–287, 1999.
  2. Imai K, Ratkovic M. 2013. Estimating treatment effect heterogeneity in randomized program evaluation. Ann. Appl. Stat. 7:443–70
  3. M. Colby, T. Duchow-Pressley, J. J. Chung, and K. Tumer. Local approximation of difference evaluation functions. In Proceedings of the Fifteenth International Joint Conference on Autonomous Agents and Multiagent Systems, Singapore, May 2016
  4. Mnih A, Hinton GE. 2007. Three new graphical models for statistical language modelling. In International Conference on Machine Learning, pp. 641–48. La Jolla, CA: Int. Mach. Learn. Soc.
  5. O. Bardou, N. Frikha, and G. Pag`es. Computing VaR and CVaR using stochastic approximation and adaptive unconstrained importance sampling. Monte Carlo Methods and Applications, 15(3):173–210, 2009.
  6. V. Borkar. Q-learning for risk-sensitive control. Mathematics of Operations Research, 27:294–311, 2002.
  7. Athey S, Imbens GW. 2017b. The state of applied econometrics: causality and policy evaluation. J. Econ. Perspect. 31:3–32

Premium

  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

Login
This project is licensed under the license; additional terms may apply.